136 results on '"Engert, Andreas"'
Search Results
2. Phase II study of fixed‐duration single‐agent ibrutinib in relapsed nodular lymphocyte‐predominant Hodgkin lymphoma: A report from the German Hodgkin Study Group
3. JAK inhibition with ruxolitinib in relapsed or refractory classical Hodgkin lymphoma: Final results of a phase II, open label, multicentre clinical trial (JeRiCHO)
4. Tumour cell characteristics and microenvironment composition correspond to clinical presentation in newly diagnosed nodular lymphocyte‐predominant Hodgkin lymphoma
5. Outcomes of anti‐programmed death 1 treatment for relapsed/refractory Hodgkin lymphoma: A German Hodgkin Study Group multicentre real‐world analysis
6. Impact of bone marrow involvement on early positron emission tomography response and progression‐free survival in the HD18 trial for patients with advanced‐stage Hodgkin lymphoma
7. Reinduction therapy with everolimus in combination with dexamethasone, high‐dose cytarabin and cisplatinum in patients with relapsed or refractory classical Hodgkin lymphoma: an experimental phase I/II multicentre trial of the German Hodgkin Study Group (GHSG HD‐R3i)
8. 9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial
9. Histopathological growth patterns in patients with advanced nodular lymphocyte‐predominant Hodgkin lymphoma treated within the randomized HD18 study: a report from the German Hodgkin Study Group
10. Non‐Hodgkin lymphoma after treatment for classical Hodgkin lymphoma: a report from the German Hodgkin Study Group
11. Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies
12. Open Access is the Plan S Way Forward in Hematology Research
13. Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies
14. The time to relapse correlates with the histopathological growth pattern in nodular lymphocyte predominant Hodgkin lymphoma
15. Treatment of elderlyHodgkin lymphoma patients
16. Phase I study of domatinostat (4 SC ‐202), a class I histone deacetylase inhibitor in patients with advanced hematological malignancies
17. Prospective study of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma patients who are not suitable for stem cell transplant or multi-agent chemotherapy
18. Whole genome sequencing reveals DICER1 as a candidate predisposing gene in familial Hodgkin lymphoma
19. Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer)
20. Affordability of Medicines a Top Priority for EHA
21. Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression-free survival: individual participant data analysis
22. Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma
23. Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma
24. Interim PET for prognosis in adults with Hodgkin lymphoma: a prognostic factor exemplar review
25. Leucocyte and eosinophil counts predict progression-free survival in relapsed or refractory classical Hodgkin Lymphoma patients treated with PD1 inhibition
26. Nivolumab for adult individuals with Hodgkin lymphoma (an exemplar rapid review using RobotReviewer)
27. Purine analogues plus cyclophosphamide versus purine analogues alone for first-line therapy of patients with chronic lymphocytic leukaemia
28. Low dose cytarabine monotherapy for myelodysplastic syndromes
29. High-dose chemotherapy with autologous stem cell support for first-line treatment of aggressive non-Hodgkin lymphoma: a systematic review and meta-analysis based on individual patient data
30. Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement: An international multicenter collaboration
31. Granulocyte and granulocyte-macrophage colony stimulating factors for newly diagnosed patients with myelodysplastic syndromes
32. Antibiotics for the prevention of infections in cancer patients receiving myelosuppressive chemotherapy or haematopoetic stem cell transplantation
33. Idiotype vaccination for Non-Hodgkin lymphoma
34. Intravenous immunoglobulins for the treatment of infections in patients with haematological cancers
35. Low dose cytarabine monotherapy for acute myeloid leukaemia
36. Hypomethylating agents for patients with myelodysplastic syndrome
37. Hypomethylating agents for adult patients with acute myeloid leukaemia
38. Prophylactic antibiotics or G(M)-CSF for the prevention of infections and improvement of survival in cancer patients receiving myelotoxic chemotherapy
39. Effects of all-trans retinoic acid (ATRA) in addition to chemotherapy for adults with acute myeloid leukaemia (AML) (non-acute promyelocytic leukaemia (APL))
40. Additional plerixafor to granulocyte colony-stimulating factors for haematopoietic stem cell mobilisation for autologous transplantation in people with malignant lymphoma or multiple myeloma
41. Impact of centralized diagnostic review on quality of initial staging in Hodgkin lymphoma: experience of the German Hodgkin Study Group
42. XVII. Treatment of advanced-stage Hodgkin lymphoma
43. Mindfulness-based stress reduction for women diagnosed with breast cancer
44. Positron emission tomography-adapted therapy for first-line treatment in individuals with Hodgkin lymphoma
45. Aerobic physical exercise for adult patients with haematological malignancies
46. Histopathological features and their prognostic impact in nodular lymphocyte-predominant Hodgkin lymphoma - a matched pair analysis from the German Hodgkin Study Group (GHSG)
47. The role of additional radiotherapy for primary central nervous system lymphoma
48. Yoga in addition to standard care for patients with haematological malignancies
49. Antibodies and antibody-drug conjugates in the treatment of Hodgkin lymphoma
50. Protrusion-guided extracellular vesicles mediate CD30 trans-signalling in the microenvironment of Hodgkin's lymphoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.